AstraZeneca PLC (AZNCF)

Market Cap	296.35B
Revenue (ttm)	58.13B +13.5%
Net Income	9.40B +44.7%
EPS	6.02 +45.0%
Shares Out	n/a
PE Ratio	31.53
Forward PE	19.02
Dividend	3.13 (1.61%)
Ex-Dividend Date	Aug 7, 2025

Volume	n/a
Average Volume	1,746
Open	195.00
Previous Close	179.05
Day's Range	195.00 - 195.00
52-Week Range	122.26 - 195.00
Beta	0.19
RSI	55.11
Earnings Date	Feb 10, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: OTCMKTS
• Ticker Symbol: AZNCF

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.